{
    "clinical_study": {
        "@rank": "94104", 
        "arm_group": [
            {
                "arm_group_label": "Droxidopa", 
                "arm_group_type": "Active Comparator", 
                "description": "Droxidopa 100 mg, 200 mg, 300 mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluate the clinical efficacy and safety of droxidopa versus placebo over a 17 week\n      (maximum) treatment period in patients with symptomatic NOH."
        }, 
        "brief_title": "A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Symptomatic Neurogenic Orthostatic Hypotension", 
            "Parkinson's Disease", 
            "Multiple Systems Atrophy", 
            "Pure Autonomic Failure", 
            "Dopamine Beta Hydroxylase Deficiency"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypotension", 
                "Hypotension, Orthostatic", 
                "Parkinson Disease", 
                "Multiple System Atrophy", 
                "Shy-Drager Syndrome", 
                "Atrophy", 
                "Autonomic Nervous System Diseases", 
                "Pure Autonomic Failure"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a multi-center, multi-national, randomized, parallel-group, placebo-controlled,\n      double-blind study with a 17 week (maximum) treatment period consisting of an initial,\n      open-label dose titration (up to 2 weeks), followed by a washout period (up to 3 weeks),\n      followed by a 12 week treatment period on a stable dose."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. 18 years and older and ambulatory (defined as able to walk at least 10 meters);\n\n             2. Clinical diagnosis of symptomatic orthostatic hypotension associated with Primary\n             Autonomic Failure (PD, MSA and PAF), Dopamine Beta Hydroxylase Deficiency;\n\n             3. At the Baseline visit (Visit 2), patients must demonstrate:\n\n               1. a score of at least 4 or greater on the Orthostatic Hypotension Symptom\n                  Assessment (OHSA) Item #1;\n\n               2. a fall of at least 20 mmHg in their systolic blood pressure, within 3 minutes of\n                  standing;\n\n                  4. Provide written informed consent to participate in the study and understand\n                  that they may withdraw their consent at any time without prejudice to their\n                  future medical care;\n\n                  Exclusion Criteria:\n\n          -  1. Score of 23 or lower on the mini-mental state examination (MMSE);\n\n             2. Concomitant use of vasoconstricting agents for the purpose of increasing blood\n             pressure;\n\n               1. Patients taking vasoconstricting agents such as ephedrine, dihydroergotamine, or\n                   midodrine must stop taking these drugs at least 2 days or 5 half-lives\n                  (whichever is longer) prior to their baseline visit (Visit 2) and throughout the\n                  duration of the study;\n\n                  3. Known or suspected alcohol or substance abuse within the past 12 months\n                  (DSM-IV definition of alcohol or substance abuse);\n\n                  4. Women who are pregnant or breastfeeding;\n\n                  5. Women of child bearing potential (WOCP) who are not using at least one method\n                  of contraception with their partner;\n\n                  6. Male patients who are sexually active with a woman of child bearing potential\n                  (WOCP) and not using at least one method of contraception;\n\n                  7. Untreated closed angle glaucoma;\n\n                  8. Diagnosis of hypertension that requires treatment with antihypertensive\n                  medications (short-acting  antihypertensives to treat nocturnal supine HTN are\n                  allowed in this study) Any significant uncontrolled cardiac arrhythmia;\n\n                  9. History of myocardial infarction, within the past 2 years;\n\n                  10. Current unstable angina;\n\n                  11. Congestive heart failure (NYHA Class 3 or 4);\n\n                  12. History of cancer within the past 2 years other than a successfully treated,\n                  non-metastatic cutaneous squamous cell or basal cell carcinoma or cervical\n                  cancer in situ;\n\n                  13. Gastrointestinal condition that may affect the absorption of study drug\n                  (e.g. ulcerative colitis, gastric bypass);\n\n                  14. Any major surgical procedure within 30 days prior to the Baseline visit\n                  (Visit 2);\n\n                  15. Previously treated with droxidopa within 30 days prior to the Baseline visit\n                  (Visit 2);\n\n                  16. Currently receiving any other investigational drug or have received an\n                  investigational drug within 30 days prior to the Baseline visit (Visit 2);\n\n                  17. Any condition or laboratory test result, which in the Investigator's\n                  judgment, might result in an increased risk to the patient, or would affect\n                  their participation in the study;\n\n                  18. The Investigator has the ability to exclude a patient if for any reason they\n                  feel the subject is not a good candidate for the study or will not be able to\n                  follow study procedures."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01927055", 
            "org_study_id": "NOH401"
        }, 
        "intervention": [
            {
                "arm_group_label": "Droxidopa", 
                "description": "Droxidopa at 100 mg, 200 mg, 300 mg", 
                "intervention_name": "Droxidopa", 
                "intervention_type": "Drug", 
                "other_name": "L-threo-3,4-dihydroxyphenylserine, L-threo-DOPS, or L-DOPS"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo to match droxidopa capsules and strength designations", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Mannitol"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Droxidopa"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "NOH", 
            "OH", 
            "PD", 
            "MSA", 
            "PAF", 
            "DBH"
        ], 
        "lastchanged_date": "November 13, 2013", 
        "location": [
            {
                "contact": {
                    "email": "Horacio.Kaufmann@med.nyu.edu", 
                    "last_name": "Horacio Kaufmann, M.D.", 
                    "phone": "212-263-7225"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "NYU Langone Medical Center"
                }, 
                "investigator": {
                    "last_name": "Horacio Kaufmann, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "szakacs@chelseaRx.com", 
                    "last_name": "Cameron Szakacs, Ph. D.", 
                    "phone": "704-973-4203"
                }, 
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28277"
                    }, 
                    "name": "Information on additional locations involved in this clinical trial contact Chelsea Therapeutics"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jklein@parkcent.com", 
                    "last_name": "Paul Nausieda, MD", 
                    "phone": "414-219-7450"
                }, 
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53233"
                    }, 
                    "name": "Wisconsin Institute for Neurology and Sleep Disorders"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy", 
        "overall_contact": {
            "email": "szakacs@chelseaRx.com", 
            "last_name": "Cameron Szakacs, Ph. D.", 
            "phone": "704-973-4203"
        }, 
        "overall_contact_backup": {
            "email": "cram@chelseaRx.com", 
            "last_name": "Charles Cram, BS", 
            "phone": "7049734213"
        }, 
        "overall_official": {
            "affiliation": "NYU Langone Medical Center", 
            "last_name": "Horacio Kaufmann, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluate the duration of clinical benefits of droxidopa as demonstrated by the change in the Orthostatic Hypotension Symptom Assessment (OHSA) Item 1", 
            "measure": "OHSA Item 1", 
            "safety_issue": "No", 
            "time_frame": "Change from Randomization to Week 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01927055"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evaluate the clinical efficacy of droxidopa as demonstrated by a difference between placebo and droxidopa in patient reported falls from Randomization to the end of study visit at Week 12", 
                "measure": "Falls", 
                "safety_issue": "Yes", 
                "time_frame": "Change from Randomization to Week 12"
            }, 
            {
                "description": "Evaluate the effect of droxidopa on standing blood pressure as demonstrated by a change from Randomization to the end of study visit at Week 12", 
                "measure": "Standing blood pressure", 
                "safety_issue": "No", 
                "time_frame": "Change from Randomization to Week 12"
            }, 
            {
                "description": "Evaluate the clinical efficacy of droxidopa as demonstrated change in disease severity using the Orthostatic Hypotension Questionnaire (OHQ) composite score and individual item scores", 
                "measure": "Orthostatic Hypotension Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Change from Randomization to Week 12"
            }, 
            {
                "description": "Evaluate the clinical efficacy of droxidopa as demonstrated by change in the clinician recorded and patient-recorded Clinical Global Impression-Severity (CGI-S) and the Clinical Global Impression-Improvement (CGI-I) scales from Randomization to the end of study visit at Week 12", 
                "measure": "Clinical Global Impression Scales", 
                "safety_issue": "No", 
                "time_frame": "Change from Randomization to Week 12"
            }, 
            {
                "description": "Evaluate the clinical efficacy of droxidopa as demonstrated by change in basic mobility using the Boston University Activity Measure for Post-Acute Care (AM-PAC) Basic Mobility Outpatient Short Form from Randomization to the end of study visit at Week 12", 
                "measure": "Boston University Activity Measure for Post-Acute Care Basic Mobility", 
                "safety_issue": "No", 
                "time_frame": "Change from Randomization to Week 12"
            }
        ], 
        "source": "Chelsea Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chelsea Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}